Aurobindo Pharma receives USFDA approval for gastro reflux drug
The company said the launch of the product is based on the settlement terms/litigation outcome with AstraZeneca.
Drug firm Aurobindo Pharma has received final approval from USFDA to manufacture and market Esomeprazole Magnesium delayed release capsules, used in a treatment of gastroesophageal reflux disease, in the American market.
The company said the launch of the product is based on the settlement terms/litigation outcome with AstraZeneca.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Esomeprazole Magnesium delayed-release capsules USP, 20 mg and 40 mg," Aurobindo Pharma said in a Bombay Stock Exchange (BSE) filing.
The approved abbreviated new drug application (ANDA) is a bio-equivalent and therapeutically equivalent to the reference listed drug product Nexium delayed-release capsules USP, 20 mg and 40 mg, of AstraZeneca Pharmaceuticals, it added.
"The approved product has an estimated market size of $4.2 billion (nearly Rs 27,941.6 crore) for the 12 months ended February 2016, according to IMS," it said.
Esomeprazole Magnesium delayed-release capsules is used in a treatment of gastroesophageal reflux disease.
Aurobindo Pharma currently has a total of 253 ANDA approvals -- 217 final approvals including 10 from Aurolife Pharma LLC and 36 tentative -- from the USFDA.
At 13:32 hours, on Friday, the shares of Aurobindo Pharma were trading up 2.40% or Rs 18.45 at Rs 786.10 per scrip on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
SBI 444-day FD vs Union Bank of India 333-day FD: Know maturity amount on Rs 4 lakh and Rs 8 lakh investments for general and senior citizens
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
PSU Oil Stocks: Here's what brokerage suggests on these 2 largecap, 1 midcap scrips - Buy, Sell or Hold?
Power of Compounding: How many years it will take to reach Rs 2 crore corpus if your monthly SIP is Rs 3,000, Rs 4,000, or Rs 5,000
Retirement Calculator: 40 years of age, Rs 50,000 monthly expenses; what should be retirement corpus and monthly investment
01:55 PM IST